Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CPA1 | P15085 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4348810 | 0.96 | ALDH1A1 (0.34) | ALDH1A1MEN1LMNAKMT2ACPA1 | |
| SCHEMBL4330758 | 0.95 | ALDH1A1 (0.33) | ALDH1A1MEN1LMNAKMT2ACPA1 | |
| SCHEMBL4337131 | 0.87 | ALDH1A1 (0.33) | ALDH1A1MEN1LMNAKMT2ASLC6A2 | |
| SCHEMBL1153095 | 0.84 | PSEN1 (0.33) | ALDH1A1MEN1LMNAKMT2ASLC6A2 | |
| SCHEMBL1153545 | 0.84 | PSEN1 (0.35) | ALDH1A1MEN1LMNAKMT2ASLC6A2 | |
| SCHEMBL4339821 | 0.84 | ALDH1A1 (0.33) | ALDH1A1MEN1LMNAKMT2ACPA1 | |
| SCHEMBL1153440 | 0.83 | PSEN1 (0.34) | ALDH1A1MEN1LMNAKMT2ASLC6A2 | |
| SCHEMBL1153671 | 0.83 | PSEN1 (0.34) | ALDH1A1MEN1LMNAKMT2ASLC6A2 | |
| SCHEMBL4343510 | 0.83 | CTSL (0.32) | ALDH1A1MEN1LMNAKMT2ASLC6A2 | |
| SCHEMBL4344275 | 0.82 | RXFP1 (0.35) | ALDH1A1MEN1LMNAKMT2ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612236-B2 | Method for producing optically active bisamidoalcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20070100163-A1 | Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-05-03 | — | — | US | disclosed |
| EP-1698616-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BISAMIDO ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100163-A1 | Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced | CCNL2, ARL1, ACSL3 | ALDH1A1 1303/4885MEN1 1168/4885LMNA 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.